ARTICLE | Product Development
Payers’ view of reimbursement when gene therapy isn’t enough
SMA will be a testing ground for when and if payers reimburse for combinations involving a gene therapy
August 10, 2019 2:14 AM UTC
Spinal muscular atrophy is giving payers a new conundrum, and the indication is poised to become a testing ground with implications for many if not all gene therapies.
The issue is whether, and how, payers will reimburse for both a one-time gene therapy and a chronic therapy for the same setting...